Invasive lobular breast carcinoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:32:50 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Invasive lobular breast carcinoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Capivasertib and Fulvestrant for Patients with High-Risk Lobular Breast Cancer https://clinicaltrials.eu/trial/study-of-capivasertib-and-fulvestrant-for-patients-with-high-risk-lobular-breast-cancer/ Wed, 29 Apr 2026 14:29:44 +0000 https://clinicaltrials.eu/trial/study-of-capivasertib-and-fulvestrant-for-patients-with-high-risk-lobular-breast-cancer/ This clinical trial is focused on studying treatments for primary high-risk lobular breast cancer. The study will evaluate the effectiveness of two medications: Fulvestrant, which is a solution for injection, and Capivasertib, which is a film-coated tablet. Fulvestrant works as a competitive estrogen receptor antagonist, while Capivasertib is a potent and selective oral inhibitor of all three isoforms of the serine/threonine kinase AKT. The purpose of the study is to assess the ability of these treatments to stop the cancer cell cycle completely.

Participants in the study will receive either Fulvestrant alone or a combination of Fulvestrant and Capivasertib. The study will last for approximately 10 weeks, during which the effects of the treatments on the cancer will be closely monitored. The main goal is to see if the treatments can reduce the activity of a protein called Ki67 to less than 2.7%, which indicates a complete cell cycle arrest. This will be assessed by examining breast tissue samples.

Secondary goals of the study include evaluating the absence of any remaining cancer cells in the breast and lymph nodes after treatment, known as a pathological complete response. The study will also look at how long participants remain free from invasive disease and overall survival rates. These outcomes will help determine the effectiveness of the treatments in managing high-risk lobular breast cancer.

]]>